Hepatitis A - Pipeline Review, H1 2017

Date: May 16, 2017
Pages: 25
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H43893D49F8EN
Leaflet:

Download PDF Leaflet

Hepatitis A - Pipeline Review, H1 2017
Hepatitis A - Pipeline Review, H1 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis A - Pipeline Review, H1 2017, provides an overview of the Hepatitis A (Infectious Disease) pipeline landscape.

Hepatitis A is inflammation of the liver caused by hepatitis A virus. Symptoms include fatigue, nausea and vomiting, inflammation of the liver, loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes (jaundice). Risk factors include weakened immune system and use injected or non-injected illicit drugs. Treatment includes antiemetics and pain relievers.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis A - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hepatitis A (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis A (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, IND/CTA Filed and Preclinical stages are 1, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Hepatitis A (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis A (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis A (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis A (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis A (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis A (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis A (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis A (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Hepatitis A - Overview
Hepatitis A - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hepatitis A - Therapeutics Assessment
Assessment by Target
Assessment by Molecule Type
Hepatitis A - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Indian Immunologicals Ltd
Sinovac Biotech Ltd
Zydus Cadila Healthcare Ltd
Hepatitis A - Drug Profiles
(hepatitis A + hepatitis B + hepatitis E) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(hepatitis A + hepatitis B) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A + hepatitis B vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatitis A - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Hepatitis A, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Hepatitis A - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
Hepatitis A - Pipeline by Indian Immunologicals Ltd, H1 2017
Hepatitis A - Pipeline by Sinovac Biotech Ltd, H1 2017
Hepatitis A - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
Hepatitis A - Dormant Projects, H1 2017

LIST OF FIGURES

Number of Products under Development for Hepatitis A, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

COMPANIES MENTIONED

Beijing Minhai Biotechnology Co Ltd
Indian Immunologicals Ltd
Sinovac Biotech Ltd
Zydus Cadila Healthcare Ltd
Skip to top


Hepatic Encephalopathy - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 64 pages
Hepatitis B - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 389 pages

Ask Your Question

Hepatitis A - Pipeline Review, H1 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: